iShares Nasdaq Biotechnology ETF (IBB) - NASDAQ
  • Fri, May 6, 11:32 AM
    • Ignoring the healthy number of product approvals, sexy technologies and encouraging growth prospects, biotech investors continue to head for the exits. The iShares Nasdaq Biotechnology ETF (IBB -2%) has lost almost 13% of its value in less than two weeks. The main culprit appears to be concerns over drug pricing, in the crosshairs of Congress and stoked by presidential candidate Hillary Clinton. Until recently, led by the mess at Valeant Pharmaceuticals (VRX -9.7%), drug makers were driving sales and profits with aggressive price hikes.
    | Fri, May 6, 11:32 AM | 26 Comments
  • Thu, Mar. 17, 3:08 PM
    • With the S&P 500 returning to more or less flat on the year, Bespoke digs down into sector performance and finds most of them nicely in the green, including the roughed-up energy group (NYSEARCA:XLE) with a 5.9% gain.
    • Leading on the upside, though, are the telecoms (NYSEARCA:XTL), ahead 14.4%, and utilities (NYSEARCA:XLU), up 13.3%. Consumer Staples (NYSEARCA:XLP), Materials (NYSEARCA:XLB), and Industrials (NYSEARCA:XLI) are all up between 3.7% and 4.5%, while Consumer Discretionary (NYSEARCA:XLY) is flat.
    • Holding the S&P 500 back, then, is healthcare (NYSEARCA:XLV), with an 8.2% decline, and financials (NYSEARCA:XLF), down 5.5%. Within, healthcare, the biotechs (NASDAQ:IBB) have plunged 27%.
    | Thu, Mar. 17, 3:08 PM
  • Wed, Jan. 27, 3:30 PM
    • As if biotech investors need reminding, biotechs (and healthcare stocks) are getting some rude treatment today, the market's foul mood notwithstanding. The Nasdaq Composite Index is down 2.5%,but the SPDR S&P Biotech ETF (XBI -4.7%) almost twice as much. The iShares Nasdaq Biotechnology ETF (IBB -3.5%) is faring a bit better, but still down more than the broad market.
    • Only Biogen and Abbott have bucked the trend.
    • Sample of tickers: (AMGN -2.5%)(BIIB +5.7%)(CELG -3.9%)(GILD -3.3%)(ALXN -1.2%)(ABT +0.3%)(BMY -1.8%)(MRK -3%)(VRX -4%)(PFE -0.9%)
    • ETFs: BIB, BIS, CNCR
    | Wed, Jan. 27, 3:30 PM | 63 Comments
  • Wed, Jan. 20, 1:47 PM
    • It appears that biotech investors have had enough of the sidelines. Many tickers are showing bullish reversals.
    • Representative tickers: (RLYP +15.3%)(CELG +2.6%)(AMGN +0.2%)(BIIB -1.6%)(ALXN -0.6%)(VRTX +0.2%)(IBB +0.8%)(XBI +2.1%)
    | Wed, Jan. 20, 1:47 PM | 20 Comments
  • Wed, Jan. 20, 11:36 AM
    • To point out the obvious, the biotech sector has been unable to fight off the widespread selling. The iShares Nasdaq Biotech Index Fund (IBB -1.8%) is down again, albeit on modestly higher volume. It's down over 21% since late December.
    • Representative tickers: (GILD -1.7%)(CELG +0.7%)(BIIB -2.7%)(AMGN -0.6%)(ALXN -2.8%)
    | Wed, Jan. 20, 11:36 AM | 17 Comments
  • Thu, Jan. 14, 10:57 AM
    • Biotechs are moving in sync with the market today. The iShares Nasdaq Biotech Index Fund (IBB +1.8%) is up ~4% from its low of 273.47, outpacing the Nasdaq Composite's 2.6% jump from its intraday low of 4,470.59. The IBB had lost over 20% of its value since late December.
    • ETFs: BIB, GRX, IRY, BIS, IXJ, BME, CNCR, THW
    | Thu, Jan. 14, 10:57 AM | 2 Comments
  • Thu, Jan. 7, 10:22 AM
    • Biotech's traditional role as a (relative) safe haven during market weakness ain't holding up lately. The iShares Nasdaq Biotech Index (IBB -2.6%) is down almost 3% today in early trading and down almost 10% since late December, a sharper drop than the Nasdaq composite's 7% plunge.
    • Investors should be careful here. There's more to come.
    | Thu, Jan. 7, 10:22 AM | 19 Comments
  • Oct. 21, 2015, 1:22 PM
    • As if anyone following biotechs needs reminding, sellers are overwhelming the space. The iShares Nasdaq Biotechnology ETF (IBB -2.8%) is down 6% since Monday.
    • Key tickers: (BIB -6.5%)(BIS +6.3%)(VRX -38.5%)(AGN -5.9%)(BIIB -0.1%)(AMGN -1.7%)(GILD -1%)(CELG -2%)
    | Oct. 21, 2015, 1:22 PM | 66 Comments
  • Oct. 13, 2015, 3:49 PM
    • Getting out in front of what should be more bashing of their business models at the Democratic debate tonight, the healthcare names (XLV -1.3%) have about doubled the decline in the S&P 500. Within healthcare, it's the biotechs (IBB -3.1%) and pharmaceuticals (XPH -3.2%) leading the way south.
    • Celgene (CELG -3.3%), Biogen (BIIB -3.6%), Amgen (AMGN -3.5%), Allergan (AGN -4.1%), Mylan (MYL -3.6%)
    • The biotech heavy Russell 2000 (IWM -1.4%) is feeling the pain as well.
    • ETFs: IBB, IYH, XLV, XBI, VHT, PJP, BBH, FBT, HQH, CURE, XPH, HQL, PBE, FXH, RXL, IHE, FHLC, SBIO, PPH, RYH, BBC, THQ, BBP, RXD, LABU, LABD, UBIO, ZBIO
    | Oct. 13, 2015, 3:49 PM | 27 Comments
  • Sep. 30, 2015, 12:49 PM
    • Bruised and battered biotech investors get some welcome buying today as bargain hunters open their wallets. The iShares Nasdaq Biotech Index Fund (IBB +2%) is up nicely, albeit on average volume.
    • Key tickers: (AMGN +1.6%)(BIIB +2.5%)(GILD +1%)(CELG +0.7%)(DEPO +12.4%)(HZNP +8.6%)(NVO +0.7%)(AGN +4.9%)(VRX +6.4%)(REGN +0.9%)(TEVA +2%)(SHPG +2.6%)
    | Sep. 30, 2015, 12:49 PM | 26 Comments
  • Sep. 28, 2015, 12:50 PM
    | Sep. 28, 2015, 12:50 PM | 24 Comments
  • Sep. 27, 2015, 8:59 AM
    • The $8B iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell 4.9% on Friday and 13% for the week - its worst weekly performance since the height of the financial panic seven years ago. Many biotech ETFs eat the same cooking - Gilead (NASDAQ:GILD), Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), and Regeneron (NASDAQ:REGN) among the popular names - and FBT, XBI, and BBP fell in amounts similar to IBB.
    • The news flow was relatively quiet late in the week, but Hilary Clinton's promise Monday to clamp down on drug prices set things in negative motion for the momo sector.
    • Barron's Chris Dieterich reminds that a flood of biotech IPOs in recent years has filled the small cap universe with these highly speculative names, and biotech now makes up 7% of the iShares Russell 2000 Index (NYSEARCA:IWM). Indeed. The IWM fell 3.7% for the week, nearly tripling the decline of the S&P 500.
    • ETFs: IWM, TZA, TNA, UWM, VB, VBK, URTY, SCHA, TWM, IWO, RWM, SRTY, VTWO, RCG, JKJ, VTWG, TWOK, FYX, JKK, EWRS, ZSML, FYC, SMLL, RYRSX
    | Sep. 27, 2015, 8:59 AM | 127 Comments
  • Sep. 25, 2015, 3:07 PM
    | Sep. 25, 2015, 3:07 PM | 134 Comments
  • Sep. 21, 2015, 12:56 PM
    • The iShares Nasdaq Biotechnology Index Fund (IBB -5%) is down on increased volume, as well as many other ETFs and individual stocks, in apparent response by a tweet by presidential candidate Hillary Clinton stating that price gouging in the specialty drug market is outrageous. Tomorrow, she will "lay out a plan" to take it on.
    • ETFs: IBB, XBI, BBH, FBT, HQL, PBE, SBIO, BBC, BBP, LABD, UBIO, LABU, ZBIO
    | Sep. 21, 2015, 12:56 PM | 83 Comments
  • Aug. 21, 2015, 9:41 AM
    • Stating the obvious, biotechs (IBB -1%) are now officially in a correction phase. Valuations have dropped 14% since July 20 on high volume.
    • Long investors should keep their powder dry until at least a firm level of support forms.
    | Aug. 21, 2015, 9:41 AM | 11 Comments
  • Aug. 6, 2015, 3:17 PM
    • Sarepta Therapeutics (SRPT +5.8%) is up on average volume which is notable considering that the iShares Nasdaq Biotech Index Fund (IBB -3.8%) is down almost 4% and the Nasdaq nearly 2%.
    • The company completed its rolling NDA submission for lead product candidate eteplirsen for the treatment of Duchenne muscular dystrophy in late June. The FDA has 60 days to confirm its completeness for review which should happen in a few weeks.
    | Aug. 6, 2015, 3:17 PM | 1 Comment
IBB Description
The iShares Nasdaq Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index<sup>®</sup>.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub